{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-019854","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.856233+00:00","generated_at":"2026-05-26T22:14:15.383646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx Q4 revenue $165M, FY $560M; guides 2025 revenue $640-670M","bullets":["Q4 2024 total revenue $165M (+29% YoY); FY 2024 total revenue $560M (+29% YoY).","Crysvita FY revenue $410M (+25% YoY); Dojolvi FY revenue $88M (+25% YoY).","FY 2024 net loss $569M ($6.29/diluted share) vs $607M ($8.25) in 2023; cash used ops $414M.","2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M; lower cash ops expected.","PDUFA decision for UX111 gene therapy (Sanfilippo syndrome) expected H2 2025; BLA filing for DTX401 (GSDIa) mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-019854","json":"https://secwatch.observer/filing/0000950170-25-019854.json","markdown":"https://secwatch.observer/filing/0000950170-25-019854.md","text":"https://secwatch.observer/filing/0000950170-25-019854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/0000950170-25-019854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:14:15.383646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}